VCELHealthcare · BiotechnologyThe 8 Wall Street analysts covering Vericel Corp. hold a median 12-month price target of $59 — +29.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Vericel Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Value (57): The shares cost a lot relative to the profits and assets behind them.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +29.7% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Truist Securities | Maintains | Buy | $58 → $52 |
| 31 July 2026 | HC Wainwright & Co. | Maintains | Buy | $70 → $72 |
| 31 July 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2026 | TD Cowen | Maintains | Buy | $55 → $58 |
| 31 July 2026 | TD Cowen | Maintains | Buy | — |
| 31 July 2026 | Truist Securities | Reiterates | Buy | — |
| 31 July 2026 | Truist Securities | Reiterates | Buy | $54 → $58 |
| 28 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $70 |
| 28 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | $42 → $54 |
| 8 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 27 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | Truist Securities | Maintains | Buy | — |
| 10 Nov 2025 | Truist Securities | Reiterates | Buy | — |
| 15 Oct 2025 | Truist Securities | Maintains | Buy | — |
| 17 Sept 2025 | BTIG | Downgrade | Neutral | — |
| 1 Aug 2025 | Canaccord Genuity | Maintains | Buy | — |
| 16 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VCEL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Vericel Corp. returned +25.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 8% of US stocks
Cheaper than 18% of US stocks
Cheaper than 16% of US stocks
Cheaper than 3% of US stocks
Higher than 72% of US stocks
Higher than 61% of US stocks
Higher than 85% of US stocks
Higher than 46% of US stocks
Higher than 66% of US stocks
Higher than 57% of US stocks
Higher than 61% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vericel Corp. has a market value of $2.1B and an enterprise value of $2.0B.
Revenue in the twelve months to 30 June 2026: $306.3M. The latest quarter grew 22.5% year on year.
Net income over the same four quarters: $24.2M, a 7.9% net margin.
Diluted earnings per share, trailing twelve months: $0.47.
Free cash flow in the twelve months to 30 June 2026: $61.7M, after $8.0M of capital spending.
Trailing P/E: 87.4×; forward P/E: 48.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vericel Corp. employs 398 people — $770K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vericel Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vericel announced it will report third-quarter 2026 financial results on November 5, 2026. Management will discuss financial results and business highlights during a conference call and webcast at 8:30 a.m. ET.
Why it matters — VCEL watchers may note the scheduled date and time for the company's next financial update.
Vericel Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its remarks was published on Seeking Alpha. The coverage focuses on the company's participation at the conference.
Why it matters — A VCEL watcher would care because the transcript offers direct insight into the company's recent commentary and updates shared with investors at the conference.
Seeking Alpha highlights Vericel's MACI therapy, noting its established commercial base and arthroscopic delivery as growth facilitators. The article also points to the company's new BARDA contract supporting its Burn Care business, plus potential UK launch and ankle indication developments.
Why it matters — The piece underscores multiple growth catalysts for VCEL, including expanded capacity at Burlington, a new BARDA contract, and potential new market and indication launches.
Vericel Corporation announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. The company, a leader in advanced therapies for sports medicine and severe burn care, made the announcement on September 8, 2026.
Why it matters — A presentation at a major healthcare conference gives Vericel a platform to update investors and industry participants on its business, which VCEL watchers may follow for insights into the company's progress.
Vericel reported record second-quarter revenue and raised its full-year outlook, driven by growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.
Why it matters — The strong quarterly performance and upward revision to the full-year forecast signal sustained momentum in Vericel's core product lines and improving financial health.
The 8 Wall Street analysts covering Vericel Corp. have a median 12-month price target of $59, with estimates ranging from $52 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Vericel Corp., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vericel Corp. 94 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Vericel Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +29.7% from the last close, and Ticker Nerd's factor model ranks Vericel Corp. 94 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vericel Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VCEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $52 to $72 over the next 12 months.
Vericel Corp. returned +25.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026". Vericel announced it will report third-quarter 2026 financial results on November 5, 2026. Management will discuss financial results and business highlights during a conference call and webcast at 8:30 a.m. ET.
Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of damaged tissue and the restoration of function in patients with serious injuries. Its commercial portfolio includes MACI, a cell therapy used in knee cartilage repair; Epicel, a skin replacement product for severe burns; and NexoBrid, an enzymatic biologic used for eschar removal in burn care. The company serves hospitals, surgeons, and specialized care teams across the United States, with its products positioned within regenerative medicine and acute wound care. Vericel’s business centers on translating cell-based science into practical treatments for complex orthopedic and burn-related conditions.
CEO Mr. Dominick C. Colangelo Esq. · 398 employees · United States · https://www.vcel.com
